Seaport Global Securities began coverage on shares of Vanda Pharmaceuticals (NASDAQ:VNDA) in a report released on Friday morning, Marketbeat Ratings reports. The firm issued a buy rating and a $20.00 target price on the biopharmaceutical company’s stock.

Several other research analysts have also recently weighed in on VNDA. Oppenheimer reiterated a buy rating on shares of Vanda Pharmaceuticals in a research report on Monday, January 8th. Zacks Investment Research upgraded Vanda Pharmaceuticals from a hold rating to a buy rating and set a $18.00 price objective on the stock in a research report on Wednesday, October 18th. ValuEngine cut Vanda Pharmaceuticals from a hold rating to a sell rating in a research report on Thursday, October 26th. Piper Jaffray Companies set a $26.00 price objective on Vanda Pharmaceuticals and gave the stock a buy rating in a research report on Thursday, October 19th. Finally, BidaskClub upgraded Vanda Pharmaceuticals from a sell rating to a hold rating in a research report on Friday, December 22nd. Three investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Vanda Pharmaceuticals presently has an average rating of Buy and a consensus price target of $21.29.

Vanda Pharmaceuticals (VNDA) opened at $15.10 on Friday. The firm has a market capitalization of $651.45, a price-to-earnings ratio of -48.71 and a beta of 1.29. Vanda Pharmaceuticals has a 12-month low of $11.90 and a 12-month high of $18.99.

Vanda Pharmaceuticals (NASDAQ:VNDA) last posted its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, hitting the consensus estimate of ($0.10). The firm had revenue of $41.30 million for the quarter, compared to analysts’ expectations of $43.90 million. Vanda Pharmaceuticals had a negative return on equity of 10.99% and a negative net margin of 9.01%. The company’s quarterly revenue was up 7.3% compared to the same quarter last year. During the same quarter last year, the business earned ($0.01) EPS. equities analysts expect that Vanda Pharmaceuticals will post -0.44 earnings per share for the current year.

In related news, insider Mihael Hristos Polymeropoulos sold 191,760 shares of the firm’s stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $15.30, for a total value of $2,933,928.00. Following the transaction, the insider now owns 1,031,848 shares in the company, valued at $15,787,274.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO James Patrick Kelly sold 9,155 shares of the firm’s stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $15.35, for a total value of $140,529.25. Following the completion of the transaction, the chief financial officer now owns 144,721 shares in the company, valued at approximately $2,221,467.35. The disclosure for this sale can be found here. Insiders sold 209,483 shares of company stock worth $3,205,205 in the last 90 days. 7.60% of the stock is owned by company insiders.

Several hedge funds and other institutional investors have recently modified their holdings of VNDA. Rothschild Asset Management Inc. bought a new position in shares of Vanda Pharmaceuticals in the third quarter worth $23,491,000. Stonepine Capital Management LLC grew its position in Vanda Pharmaceuticals by 1,482.2% in the second quarter. Stonepine Capital Management LLC now owns 685,086 shares of the biopharmaceutical company’s stock valued at $11,167,000 after acquiring an additional 641,786 shares during the last quarter. Sei Investments Co. grew its position in Vanda Pharmaceuticals by 15,516.7% in the third quarter. Sei Investments Co. now owns 267,671 shares of the biopharmaceutical company’s stock valued at $4,792,000 after acquiring an additional 265,957 shares during the last quarter. Vanguard Group Inc. grew its position in Vanda Pharmaceuticals by 7.5% in the second quarter. Vanguard Group Inc. now owns 2,680,895 shares of the biopharmaceutical company’s stock valued at $43,698,000 after acquiring an additional 186,548 shares during the last quarter. Finally, Macquarie Group Ltd. grew its position in Vanda Pharmaceuticals by 10.9% in the third quarter. Macquarie Group Ltd. now owns 1,890,085 shares of the biopharmaceutical company’s stock valued at $33,833,000 after acquiring an additional 186,526 shares during the last quarter. Institutional investors own 88.41% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This news story was reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this news story on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this news story can be accessed at https://theolympiareport.com/2018/01/23/vanda-pharmaceuticals-vnda-now-covered-by-seaport-global-securities.html.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).

Analyst Recommendations for Vanda Pharmaceuticals (NASDAQ:VNDA)

Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.